First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access

Adrian Ebner, Santiago Gallo, Juan Castellano, Maria Filartiga, Allie Haarstad, Cory Pries, Kate Gahlbeck, Mariah Mcmahon, Camila Herrera, Martha Avila, Kem Schankereli, Rick Murphy, Mark Stenoien, Zeeshan Syedain, Haimanot Wasse

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: The long-term survival and low complication rate of autogenous fistulas for hemodialysis access is often offset by early thrombosis and slow or failed maturation leading to the use of central venous catheters. A regenerative material may have the potential to overcome these limitations. A completely biological acellular vascular conduit was investigated in this first-in-human clinical study. Methods: With approval of the ethics board and patients’ informed consent, five subjects were enrolled based on predetermined inclusion criteria. Five patients underwent implant of a novel acellular, biological tissue conduit (TRUE AVC™) in the upper arm in a curved configuration between brachial artery and axillary vein. After maturation, standard dialysis was commenced through the new access. Patients were followed up to 26 weeks with ultrasound and physical exam. Serum samples were evaluated for an immune response to the novel allogeneic human tissue implant. Results: This new tissue conduit handled well surgically, with properties similar to that of native human vein. Post procedure conduit flow was excellent in all cases, averaging 1098 ± 388 ml/min at week 4 and remaining stable through 1248 ± 355 ml/min at 26 weeks. Surgical site healing was normal with no edema or erythema by week 4. Six-month primary assisted patency was 80% and secondary patency was 100%. Prescribed dialysis was successfully delivered without infection, and there was no significant change in conduit diameter. Serum testing showed no increase in PRA or IgG specific to the TRUE AVC. One implant required intervention at 5 months with thrombectomy and covered stent procedure. Conclusion: This first-in-human 6-month study with favorable patency and low complication rate establishes the initial safety and feasibility of this novel biological tissue conduit for dialysis access in patients with end-stage kidney disease. Its mechanical durability and lack of immune response establishes TRUE AVC as a potential regenerative material for clinical use.

Original languageEnglish (US)
JournalJournal of Vascular Access
StateAccepted/In press - 2023

Bibliographical note

Funding Information:
The author(s) disclosed the receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by Vascudyne Inc.

Publisher Copyright:
© The Author(s) 2023.


  • AV fistula
  • Biomaterials
  • prosthetic grafts

PubMed: MeSH publication types

  • Journal Article


Dive into the research topics of 'First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access'. Together they form a unique fingerprint.

Cite this